1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

  • May 2016
  • 275 pages
  • ID: 3948176
  • Format: PDF
  • By Visiongain


Table of Contents

Report Details
Emerging Biological Drugs – This New Study Reveals Selling Opportunities and Revenue Prospects to Help You Stay Ahead
What is the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your influence. And you explore trends, developments, results, opportunities and sales predictions.

Visiongain’s new study reveals what is possible for biological drugs – their lucrative next phase. That survey helps you avoid missing out. Instead find developments in that industry and market, discovering expected progress and revenues. Discover where the money lies.

New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, seeing how high revenues can go.

Forecasting and other information showing the most promising opportunities for treatments
Our updated report gives sales forecasts to 2026 at overall world, submarket, product and national level. You see what the future holds, assessing gains for developers and producers.

Many opportunities exist. And besides giving revenue predictions, our analysis shows you recent results, growth rates and market shares. In that report you discover 127 tables, 47 charts and four interviews with companies. See, from 2016, what is possible.

In our study you get intelligence on competitors and their activities, especially products, deals and R&D. The following sections explain what that new investigation gives you.

Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what is happening and what is possible from 2016.

Our analysis benefits your plans, decisions and influence by interpreting medical needs, R&D and companies’ technologies. There you hear what is happening, assessing opportunities and likely gains.

With those analyses you see where potential and money lie, also saving time and effort. That way you can also benefit your reputation for technological and commercial insight. The following sections explain how our study helps your work.

Prospects for that world market and submarkets – discover what is possible for next-generation biopharmaceuticals
In our report you see overall world sales to 2026 for those emerging biotherapies, exploring our discussions.

Also you gain individual revenue predictions to 2026 for six next-generation biologic submarkets at world level and their further subdivisions:
- Next-generation antibody therapies, including the subsectors of antibody-drug conjugates (ADCs), engineered antibodies and bispecific treatments
- Next-generation antibody fragments and antibody-like proteins (ALPs)
- Next-generation insulins, including submarkets assessing oral insulins, ultra-long and ultra-rapid acting therapies
- Next-generation recombinant coagulation factors
- Next-generation growth hormones
- Regenerative medicine, including tissue engineering, gene therapies and stem cells.

Our study also explores competition. There you see what is happening for developers, producers and sellers of new-generation biologics, understanding challenges, trends and outlooks. Explore what is possible.

That work also splits its overall world market into leading products, showing where you could profit from new and improved biotechnological medicines.

Product forecasts for new forms, variations and uses of biological therapy
How will individual drugs perform to 2026 at world level? Our report predicts revenues of eight top brands:
- Kadcyla
- Adcetris
- Tresiba
- Alprolix
- Eloctate
- Gazyva/Gazyvaro
- Plegridy
- Afrezza.

There you explore products and years with highest predicted sales. You also examine competitors. Hear what is happening, understanding challenges, trends, competition and opportunities.

For treating people and saving lives, you investigate progress, needs and possibilities. Discover how pharma companies satisfy those demands, also assessing expected financial gains from 2016.

Our work also shows you geographical revenue forecasts.

Demand in national markets – what outlooks for business in new biopharma products?
Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Many opportunities exist for new, improved treatments.

Our analyses show you individual revenue forecasts to 2026 for nine national markets:
- United States
- Japan
- Germany, France, United Kingdom, Italy and Spain
- China
- India.

There you hear about the best sales potentials, appraising national opportunities for next-generation biologics. See where revenues can rise, finding how you could gain.

And what events influence the biological drugs industry? What is the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges and opportunities.

Market forces and issues – what affects biopharma developers, producers and sellers?
The report explains trends, processes and events affecting the follow-on biopharmaceuticals industry and market from 2016, including these forces:
- Demands and needs for new biological therapies
- Limitations of existing medicines
- Promise of next-generation biologics and product launches
- Extension of half-life – pegylation and other technologies
- Contract manufacturers (CMOs) serving those developmental needs and trends.

And you explore these influences, among others:
- Disease incidence and prevalence affecting demand for those new medicines
- Improvements in therapeutic antibodies and variants, including targeted cytotoxic therapies
- R&D pipelines – e.g. for immunotoxins – including agents in clinical development
- Biosimilars and other follow-on protein agents transforming the biologics market
- Effects of rising incidence rates in diabetes, cardiovascular disorders and cancer.

There discover what the future holds. That way you investigate political, economic, social and technological questions. And you find how R&D helps companies benefit patients.

With our study you explore what progress, trends and opportunities mean. And you discover what helps and hinders participants in the biomedical industry, affecting companies’ results.

Biological drug technology and applications – companies and 2020 market value
What happens next? From 2016, novel follow-on treatments will benefit patients, healthcare providers and biomedical companies. Those advances will encourage investments, progress and higher revenues from more-advanced biological drugs. Discover what is possible.

Our study predicts the next-generation biologics market will reach $21.3bn worldwide in 2020, with strong revenue growth to 2026. See what the future holds for those products.

That work explores activities of these leading companies, among many other biopharmaceutical developers and producers:
- Novo Nordisk
- Eli Lilly
- Bayer
- Sanofi
- Pfizer.

In that market large pharmaceutical corporations and smaller biopharma specialists can win. See how, exploring what is possible.

You also gain interviews with four companies – Ablynx, Crescendo Biologics, Sorrento Therapeutics and Affibody – helping you stay ahead in knowledge. Discover what is happening. See what organisations shaping that industry do, helping you succeed.

5 Ways Next-Generation Biologics Market 2016-2026 helps your analyses, plans and decisions
In these five main ways our new investigation helps you gain recognition for insight, benefiting your authority:
- Revenues to 2026 at world level, for 17 market segments and 8 products – explore outlooks for R&D, production, marketing and sales
- Forecasts to 2026 for 9 national markets in North America, Europe and Asia – assess countries for revenues and sales growth opportunities
- Prospects for established competitors, rising companies and new entrants – investigate R&D, product portfolios, results and strategies
- Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages
- Interviews with 4 companies shaping that industry – discover what authorities say and do, helping you stay ahead in knowledge and succeed.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and prospects.

Trying our study now lets you discover biological drug trends, opportunities and forecasts
With our new report, by visiongain’s UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of next-generation biomedicines. Find data you get nowhere else.

Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for next-phase biopharmaceuticals. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on